Alsucral Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

alsucral

pacific pharmaceuticals limited (part of mylan) - sucralfate 0.5 g - chewable tablet - 0.5 g - active: sucralfate 0.5 g

Alsucral  (Pacific) Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

alsucral (pacific)

pacific pharmaceuticals limited (part of mylan) - sucralfate - tablet - 0.5g, 1.0g - active: sucralfate

Alsucral Powder Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

alsucral powder

pacific pharmaceuticals limited (part of mylan) - sucralfate 1 g - powder for oral solution - 1 g - active: sucralfate 1 g

SUCRALFATE- sucralfate tablet Bandaríkin - enska - NLM (National Library of Medicine)

sucralfate- sucralfate tablet

pd-rx pharmaceuticals, inc. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g - sucralfate is indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate is contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.

SUCRALFATE- sucralfate suspension Bandaríkin - enska - NLM (National Library of Medicine)

sucralfate- sucralfate suspension

cardinal health - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g in 10 ml - sucralfate suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. there are no known contraindications to the use of sucralfate.